NASDAQ · MLECW
Moolec Science SA Warrant financials
$0.0134−11.26%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 |
|---|---|---|---|
| Revenue | $333.6M | $466.4M | $420.9M |
| Gross profit | $130.2M | $187.0M | $185.4M |
| Gross margin | 39.0% | 40.1% | 44.1% |
| Operating income | -$69.0M | $40.2M | $49.6M |
| Net income | -$111.5M | -$32.7M | $40.4M |
| Net margin | −33.4% | −7.0% | 9.6% |
| Diluted EPS | $-258.69 | $-84.22 | $132.05 |
| EBITDA | -$46.7M | $61.5M | $69.1M |
| Operating cash flow | $3.6M | $39.6M | -$41.2M |
| Free cash flow | -$2.0M | $29.6M | -$52.7M |
| Diluted shares | 0.4M | 0.4M | 0.3M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|
| Cash & equivalents | $767.9K | $53.0M | $2.5M |
| Short-term investments | $0.00 | $0.00 | $306.0K |
| Total debt | $246.8M | $442.9M | $2.6M |
| Total assets | $204.7M | $949.8M | $24.1M |
| Total liabilities | $287.6M | $699.8M | $13.9M |
| Shareholders' equity | -$82.9M | $250.0M | $10.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology